Proteomic profiling identifies biomarkers predicting therapeutic response in melanoma, highlighting potential for improved patient outcomes.
Background: Immune checkpoint inhibitors (ICI) have significantly improved outcomes for patients with advanced melanoma; however, reliable biomarkers predicting therapeutic response remain limited. Proteomic profiling provides a powerful approach to capture functional molecular alterations directly at the protein level.
No takes yet. Share an insight, caveat, or question.
Teixeira et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: